SCHEMBL9419633

SCHEMBL9419633

CCN(CC)CCCN1c2ccccc2Oc2ccccc21

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 2/20 0.71
KMT2A Q03164 2/20 0.71
MEN1 O00255 1/20 0.71
TDP1 Q9NUW8 1/20 0.71
SIGMAR1 Q99720 2/20 0.59
SMPD1 P17405 3/20 0.52
P2RX4 Q99571 2/20 0.45
CHRM2 P08172 3/20 0.44
HTR1A P08908 3/20 0.44
DRD1 P21728 3/20 0.44
SLC6A4 P31645 3/20 0.44
DRD3 P35462 3/20 0.44
ADRA2A P08913 2/20 0.44
PTGS1 P23219 1/20 0.44
MAOB P27338 1/20 0.43
POLB P06746 1/20 0.43
ALDH1A1 P00352 4/20 0.43
KDM4E B2RXH2 3/20 0.43
ALOX15 P16050 2/20 0.43
HPGD P15428 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9419622 0.95 PIM1 (0.78) PIM1KMT2AMEN1TDP1SIGMAR1
SCHEMBL8211943 0.89 KMT2A (0.59) PIM1KMT2AMEN1TDP1SIGMAR1
SCHEMBL6106184 0.88 MEN1 (0.93) PIM1KMT2AMEN1TDP1SIGMAR1
SCHEMBL13305235 0.85 MEN1 (0.65) PIM1KMT2AMEN1TDP1SIGMAR1
SCHEMBL2269389 0.84 MEN1 (1.00) PIM1KMT2AMEN1TDP1SIGMAR1
SCHEMBL29767032 0.84 MEN1 (1.00) PIM1KMT2AMEN1TDP1SIGMAR1
SCHEMBL30718485 0.83 SIGMAR1 (0.67) PIM1KMT2AMEN1TDP1SIGMAR1
SCHEMBL29277409 0.83 SIGMAR1 (0.67) PIM1KMT2AMEN1TDP1SIGMAR1
Hydrochloric Acid SCHEMBL1559590 0.83 MEN1 (0.98) PIM1KMT2AMEN1TDP1SIGMAR1
Hydrochloric Acid SCHEMBL29358850 0.83 MEN1 (0.98) PIM1KMT2AMEN1TDP1SIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5371081-A Useful in potentiating the cytotoxic effect of chemotherapeutic agents ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) 1994-12-06 US claimed
WO-1993003729-A1 N-SUBSTITUTED PHENOXAZINES FOR TREATING MULTIDRUG RESISTANT CANCER CELLS RESEARCH CORPORATION TECHNOLOGIES, INC. (US) 1993-03-04 WO claimed
US-9012217-B2 Benzimidazole compounds differentiate a mammalian stem cell into mesodermal or cardiomyocyte cells BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) 2015-04-21 US disclosed
US-9012217-B2 Benzimidazole compounds differentiate a mammalian stem cell into mesodermal or cardiomyocyte cells BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) 2015-04-21 US disclosed
US-20100159596-A1 SMALL MOLECULE COMPOUNDS FOR STEM CELL DIFFERENTIATION BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) 2010-06-24 US disclosed
US-20100159596-A1 SMALL MOLECULE COMPOUNDS FOR STEM CELL DIFFERENTIATION BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) 2010-06-24 US disclosed
US-5371081-A Useful in potentiating the cytotoxic effect of chemotherapeutic agents ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) 1994-12-06 US disclosed
WO-1993003729-A1 N-SUBSTITUTED PHENOXAZINES FOR TREATING MULTIDRUG RESISTANT CANCER CELLS RESEARCH CORPORATION TECHNOLOGIES, INC. (US) 1993-03-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100159596-A1 SMALL MOLECULE COMPOUNDS FOR STEM CELL DIFFERENTIATION RCOR3, BRD3, BRPF3 PIM1 3277/4885KMT2A 1143/4885MEN1 1570/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.